Penumbra, Inc.
$333.46
▲
1.98%
2026-04-22 10:12:13
www.penumbrainc.com
NYQ: PEN
Explore Penumbra, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$13.1 B
Current Price
$333.46
52W High / Low
$362.41 / $221.26
Stock P/E
73.7
Book Value
$36.39
Dividend Yield
—
ROCE
11.52%
ROE
13.78%
Face Value
—
EPS
$4.52
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
4,700
Beta
0.84
Debt / Equity
15.39
Current Ratio
6.64
Quick Ratio
4.29
Forward P/E
51.67
Price / Sales
9.22
Enterprise Value
$12.62 B
EV / EBITDA
61.09
EV / Revenue
8.99
Rating
Hold
Target Price
$365.79
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | GE HealthCare Technologies Inc. | $71.58 | 15.76 | $32.85 B | 0.19% | 9.93% | 22.38% | $89.77 / $59.95 | $22.77 |
| 2. | Viemed Healthcare, Inc. | $9.66 | 24.97 | $372.9 M | — | 13.1% | 11.11% | $10.06 / $5.93 | $3.72 |
| 3. | TransMedics Group, Inc. | $113.13 | 20.39 | $3.88 B | — | 11.09% | 54.24% | $156 / $84.53 | $13.81 |
| 4. | Bluejay Diagnostics, Inc. | $1.97 | — | $1.94 M | — | -115.88% | -1.17% | $16.68 / $1.65 | $9.88 |
| 5. | Phaos Technology Holdings (Caym | $1.95 | — | — | — | 214.51% | -10.73% | $7.39 / $0.53 | $-0.06 |
| 6. | HeartSciences Inc. | $2.05 | — | $6.85 M | — | -1607.2% | -3.82% | $6.47 / $1.89 | $0.83 |
| 7. | Integra LifeSciences Holdings Corporation | $11.16 | — | $875.54 M | — | 0.57% | -39.9% | $17.54 / $8.7 | $13.4 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 385.38 M | 354.69 M | 339.45 M | 324.14 M | 315.52 M | — |
| Operating Profit | 59.23 M | 48.84 M | 40.83 M | 40.35 M | 42.77 M | — |
| Net Profit | 47.34 M | 45.85 M | 45.27 M | 39.22 M | 33.68 M | — |
| EPS in Rs | 1.21 | 1.17 | 1.15 | 1 | 0.86 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.4 B | 1.19 B | 1.06 B | 847.13 M |
| Operating Profit | 189.25 M | 86.22 M | 91.77 M | 6.08 M |
| Net Profit | 177.69 M | 14.01 M | 90.95 M | -2 M |
| EPS in Rs | 4.53 | 0.36 | 2.32 | -0.05 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.83 B | 1.53 B | 1.56 B | 1.37 B |
| Total Liabilities | 398.92 M | 382.25 M | 377.36 M | 372.03 M |
| Equity | 1.43 B | 1.15 B | 1.18 B | 998.86 M |
| Current Assets | 1.22 B | 951.12 M | 915.4 M | 755.7 M |
| Current Liabilities | 183.13 M | 158.34 M | 151.14 M | 144.93 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 238.66 M | 168.48 M | 97.33 M | -55.66 M |
| Investing CF | -404.59 M | 77.62 M | -16.08 M | 54.79 M |
| Financing CF | 26.53 M | -87.01 M | 16.2 M | 11.62 M |
| Free CF | 174.93 M | 147.3 M | 82.12 M | -74.96 M |
| Capex | -63.73 M | -21.18 M | -15.21 M | -19.3 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 12.86% | 24.95% | — | — |
| Earnings Growth % | -84.59% | 4643.16% | — | — |
| Profit Margin % | 1.17% | 8.59% | -0.24% | — |
| Operating Margin % | 7.22% | 8.67% | 0.72% | — |
| Gross Margin % | 63.2% | 64.49% | 63.18% | — |
| EBITDA Margin % | 3.85% | 10.26% | 3.54% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.